Exelixis Inc. Common Stock vs ArcelorMittal SA — how do they compare? Exelixis Inc. Common Stock trades at $58.72 (market cap $14.62B), while ArcelorMittal SA trades at $64.02 (market cap $45.70B). The key difference: ArcelorMittal SA is far larger — about 3.1× Exelixis Inc. Common Stock's market cap, and ArcelorMittal SA pays a 0.98% dividend while Exelixis Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Exelixis Inc. Common Stock for 0 Days and ArcelorMittal SA for 36 Days on average.
| EXEL | MT | |
|---|---|---|
Market Cap | $14.62B | $45.70B |
Volume | 2,684,957 | 1,964,621 |
Sector | Health | Basic Materials |
52-Week High | $59.13 | $78.74 |
52-Week Low | $34.54 | $36.91 |
Typical Hold Time | 0 Days | 36 Days |
Enterprise Value | $13.95B | $55.27B |
Dividend Yield | — | 0.98% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
ArcelorMittal (MT) trades at $62.32, down 4.4% today, with technical indicators signaling bearish momentum. The stock shows mixed fundamentals with revenue declining from $79.8B in 2022 to $61.4B in 2025, though net income improved to $3.2B. Recent news highlights operational disruptions at its Ukrainian plant with a potential $1B impairment charge, while analyst consensus remains positive with a $74.33 price target.
The outlook is cautious due to geopolitical risks and declining revenue trends, but valuation metrics appear reasonable with P/E of 26.2 and P/B of 0.86. Investment opportunity exists if European operations stabilize and growth projects deliver, though investors face headwinds from steel demand volatility and ongoing Ukraine-related impairments.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Exelixis develops and commercializes medicines for cancer. Its research focuses on targeted therapies for oncology.
Read more on EXEL →ArcelorMittal SA is involved in the steel industry. The company's operating segments include NAFTA
Read more on MT →